---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005830"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:57:24.561692+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma completes NASH trial enrollment, on track for CML and obesity trials in H2 2023

## Summary
- Completed enrollment in Phase 2a DUET trial of TERN-501 (THR-β agonist) for NASH; top-line data expected Q3 2023.
- On track to initiate U.S. Phase 1 trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in H2 2023; China Phase 1 update at major oncology conference.
- IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; first-in-human obesity trial expected H2 2023 with top-line data in 2024.
- FDA Type C meeting scheduled for May 2023 to discuss non-invasive endpoints for NASH development.
- Adjusted cash balance of $293M (including $112M Dec 2022 equity financing) expected to provide runway into 2026.

## SEC filing metadata
- accession: 0000950170-23-005830
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017023005830/0000950170-23-005830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017023005830/tern-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005830
- JSON: https://secwatch.observer/filing/0000950170-23-005830.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.